- Home
- CLSK vs APLS Comparison
CLSK vs APLS Comparison
Compare CLSK & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLSK | APLS |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2008 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CLSK | APLS |
|---|---|---|
| Price | $9.90 | $20.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | $19.69 | ★ $32.16 |
| AVG Volume (30 Days) | ★ 26.3M | 2.2M |
| Earning Date | 05-11-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | $766,314,000.00 | ★ $1,003,782,000.00 |
| Revenue This Year | N/A | $31.31 |
| Revenue Next Year | $19.58 | N/A |
| P/E Ratio | ★ N/A | $34.34 |
| Revenue Growth | ★ 102.21 | 28.46 |
| 52 Week Low | $6.46 | $16.10 |
| 52 Week High | $23.61 | $30.48 |
Technical Indicators
Market Signals| Indicator | CLSK | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 42.32 |
| Support Level | $8.55 | $21.07 |
| Resistance Level | $10.46 | $24.37 |
| Average True Range (ATR) | 0.90 | 0.96 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 74.15 | 33.25 |
Price Performance
Historical ComparisonAbout CLSK CleanSpark Inc.
Cleanspark Inc. is a data center developer that, until recently, focused exclusively on bitcoin mining. The company provides scalable, energy-efficient digital infrastructure across the United States. The Company has a sole reporting segment, which is the bitcoin mining segment.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.